Abstract: The purpose is to provide selective PDE IV inhibitors which have a potent anti-asthmatic profile with excellent safety.

Abstract: An object of the present invention is to obtain an oral glycyrrhizin preparation not only manufacturable by a simple method but also having an excellent property of being absorbed from the digestive tract. In the present invention, such oral preparations are made into enteric forms wherein glycyrrhizin is admixed with an effervescent agent in combination with an absorption enhancer such as a medium-chain fatty acid or a salt thereof. In the preparation of the present invention, it is now possible to achieve an excellent absorption of glycyrrhizin from the digestive tract by addition of an effervescent agent and, moreover, the preparation can be manufactured by a simple, convenient method without special steps.

Abstract: The purpose is to provide anti-inflammatory agents which have potent pharmacological actions and exert a selective inhibitory activity on COX-2, thereby being expected to reduce adverse effects such as disorders in gastric mucosa. The present invention encompasses a compound of the formula (1): wherein R.sup.1 is hydrogen or halogen, R.sup.2 and R.sup.3 are each independently hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy or lower alkanoyloxy, R.sup.4 is lower haloalkyl or lower alkyl, X is sulfur, oxygen or NH, and Y is lower alkylthio, lower alkylsulfonyl or sulfamoyl, which exerts superior anti-inflammatory activity, and highly inhibits COX-2 induced in inflamed sites, with less inhibitory action on COX-1 present in stomach, kidney, etc. Pharmaceutical agents comprising the compound of the present invention are provided as selective COX-2 inhibitors, and anti-inflammatory agents rarely accompanying adverse actions including attacks on gastric mucosa.

Abstract: This invention is concerned with 2-ureido-benzamide compounds of the formula (1) ##STR1## in which R.sup.1 is H, halogen atom, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxy or (C.sub.1 -C.sub.4)dialkylamino and R.sup.2 is H, halogen atom, hydroxy, nitro, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxy, (C.sub.3 -C.sub.6) cycloalkylmethoxy, (C.sub.1 -C.sub.4) alkylthio, (C.sub.1 -C.sub.4) alkylsulfinyl, (C.sub.1 -C.sub.4)alkylsulfonyl or ##STR2## wherein j is an integer of from 0 to 2 and R.sup.3 and R.sup.4 are each independently H, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkanoyl, (C.sub.1 -C.sub.4)alkylsulfonyl or (C.sub.1 -C.sub.4)alkylcarbamoyl, NR.sup.3 R.sup.4 can to form a pyrrolidine, piperidine, morpholine, imidazole or pyrazole ring;X is a (C.sub.3 -C.sub.15)alkyl, (C.sub.3 -C.sub.6) cycloalkyl, (C.sub.3 -C.sub.6) cycloalkylmethyl, .omega.-(C.sub.1 -C.sub.4) alkoxy-(C.sub.1 -C.sub.4) alkyl group or ##STR3## wherein k is an integer of from 1 to 4 and R.sup.5 and R.sup.

Abstract: Unique benzothiazole derivatives which exert superior aldose redactase inhibiting actions are unexpectedly and advantageously useful in the prophylactic and therapeutic treatment of diabetic complications. A benzothiazole derivative compound of the formula (1): ##STR1## wherein X is halogen, R.sup.1 and R.sup.2, which are the same or different, are each independently hydrogen or halogen, A is a methylene group or a sulfur atom, and --B--COOR.sup.3 is a group as defined in the specification; or a pharmaceutically acceptable salt and a pharmaceutical composition comprising the same which is a useful prophylactic or therapeutic agent for the treatment of diabetic complications.

Abstract: Anti-ulcer agents containing isoprenoid derivatives are provided. The isoprenoid derivatives are represented by the formula: ##STR1## wherein: R represents a group of formula ##STR2## In the above formula, R.sub.1, R.sub.2 and R.sub.3 may be the same or different each other and each represents a hydrogen atom, a hydroxy group, a lower alkanoyloxy group, a lower alkyl group or a lower alkoxy group, provided that two or more of them do not represent hydrogen atoms at the same time; R.sub.4 and R.sub.5 may be the same or different each other and each represents a hydrogen atom, a hydroxy group or a lower alkanoyloxy group represents the signal or the double bond between the carbon atoms; m represents 0 or 1; n represents 0 or an integer of from 1 to 9, provided that the sum of m and n is an integer of from 1 to 9.

Abstract: 1-Isopropyl-3-hydroxy-5-semicarbazono-6-oxo-2,3,5,6-tetrahydroindole, inclusive of pharmacologically acceptable salts thereof, is effective for prophylaxis and treatment of cerebral apoplexy.

Abstract: A soft buccal containing (1) a medicament to be absorbed through the oral mucosa, (2) a water-soluble protein, (3) a polyhydric alcohol, and (4) a fatty acid ester or/and a carboxyvinyl polymer, has various advantages such as good feeling in use, good retainability within the mouth, slow release, improved absorbability of drug through the mucosa, improved bioavailability, etc., and therefore can be used an excellent pharmaceutical preparation for administration to the mucous membrane of the mouth.

Abstract: The present invention relates to novel N-phthalidyl-5-fluorouracil derivatives represented by the general formula ##STR1## wherein one of R.sub.1 and R.sub.2 represents phthalidyl group ##STR2## (wherein R.sub.3 is a hydrogen atom, a halogen atom or a group selected from alkoxyl groups or alkyl groups) and the other represents a hydrogen atom, an acyl group or a cyclic ether group; ##STR3## (wherein n is 1 or 2) or R.sub.1 and R.sub.2 represent the same phthalidyl group; ##STR4## (wherein R.sub.3 has the same meaning as that defined above) and provides a compound which has antitumor activity and less toxicity and can be used as a cancerocidal agent.

Abstract: An antiinflammatory and analgesic gel composition for external use which comprises 0.03 to 1.5 percent by weight of clidanac or a pharmacologically acceptable salt thereof as a pharmacologically active ingredient and 0.5 to 5.0 percent by weight of gelling agent, 0.3 to 4.0 percent by weight of a neutralizer, 30 to 60 percent by weight of a solubilizer and 35 to 65 percent by weight of water, has an excellent antiinflammatory and analgesic effect.

Abstract: 2-Oxo-phenylbutanoic acid derivatives of the general formula (I) ##STR1## wherein X is amino, hydroxy or lower alkoxy, which have an anti-inflammatory activity and low toxicity, a method for the production of the said derivatives, a pharmaceutical composition containing a therapeutically effective amount of at least one compound of the said derivatives, and the use of such compounds and compositions in therapeutics.